

Curriculum Vitae

Daniel Vasella, M.D.

Chairman and Chief Executive Officer (CEO)

Daniel Vasella, M.D., is Chairman and Chief Executive Officer (CEO) of Novartis AG. He was appointed Chairman in April 1999, having served as CEO and executive member of the Board of Directors since the merger that created Novartis in 1996. Since its founding, Dr. Vasella has led Novartis through dynamic growth to rank among the world's most successful healthcare companies, with a focused portfolio, including pharmaceuticals, vaccines and diagnostics, generics and consumer health.

During his tenure as Chairman and CEO, Dr. Vasella has enhanced the company's corporate governance policies in line with best practices and listed Novartis on the New York Stock Exchange. He has also strengthened the research capacity of Novartis in leading technologies by creating the Novartis Institute for BioMedical Research and moving the company's research headquarters to Cambridge, Massachusetts, to be closer to top scientific talent as well as patient and hospital networks. He also established The Genomics Institute of the Novartis Research Foundation, which is focused on developing therapeutics from the data generated from the mapping of the human genome.

Dr. Vasella has implemented strong pioneering initiatives to ensure access to medicines, which include the founding of the Novartis Institute for Tropical Diseases for research on neglected diseases of the developing world, the International Patient Assistance Program for the breakthrough cancer drug *Gleevec/Glivec*, the supply of the novel malaria treatment *Coartem* below cost to the World Health Organization and other institutions as well as a pledge to donate the drug therapy needed to eradicate leprosy worldwide. Furthermore, under Dr. Vasella's leadership, Novartis was one of the first multinational companies to sign the UN Global Compact initiative.

A readership survey of the Financial Times selected Dr. Vasella as the most influential European businessman of the past quarter century. Dr. Vasella was awarded The CancerCare Human Services Award, the Harvard Business School's Alumni



Daniel Vasella, M.D.

Curriculum Vitae

Achievement Award, the Appeal of Conscience Award, and the AJ Congress Humanitarian Award. He has been honored with the Ordem Nacional do Cruzeiro do Sul (Brazil) and holds the rank of Chevalier in the Ordre National de la Légion d'honneur (France).

Before the Novartis merger, Dr. Vasella was CEO of Sandoz Pharma Ltd. and a member of the Sandoz Group Executive Committee. From 1988 to 1992, he was with Sandoz Pharmaceuticals Corporation in the US, prior to which he held a number of medical positions in Switzerland. He graduated with an M.D. from the University of Bern and completed executive training at the Harvard Business School.

Dr. Vasella is a member of the Board of Directors of PepsiCo, Inc. and the Board of Alcon. He is also a member of the International Board of Governors of the Peres Center for Peace in Israel, the International Business Leaders Advisory Council for the Mayor of Shanghai, the Global Health Program Advisory Panel of the Bill & Melinda Gates Foundation and is a foreign honorary member of the American Academy of Arts and Sciences.